minocycline and Skin-Diseases

Cutaneous sarcoidosis can present in pre-existing tattoos. Previous reports suggest modest improvement with systemic or topical corticosteroids or other immunomodulating medications. Tetracyclines have anti-inflammatory properties and have been shown to be efficacious in non-tattoo associated cutaneous sarcoidosis. The pharmacology of minocycline suggests that its higher concentration in the skin may improve its efficacy in the treatment of cutaneous granulomas.. We present a case of a 35-year-old man with a history of pulmonary sarcoidosis who developed raised plaques within tattoos present for over 10 years. Skin biopsy findings revealed non-caseating granulomas consistent with cutaneous sarcoidosis. The patient was started on minocycline 100mg twice daily and had resolution of pruritus in four days and improvement of sarcoidal plaques within one week.. To our knowledge, this is the first report of cutaneous sarcoidosis in tattoos treated with minocycline. Our patient's rapid response to minocycline suggests that minocycline may be a quickly effective medication for cutaneous sarcoidosis and should be considered as a therapeutic option given its favorable side-effect profile.

Topics: Adult; Anti-Bacterial Agents; Biopsy; Diagnosis, Differential; Humans; Male; Minocycline; Sarcoidosis; Skin; Skin Diseases; Tattooing

Because calcinosis cutis is a rare syndrome, there is a notable lack of controlled clinical trials on its treatment. The efficacy of calcinosis treatment has only been reported in single cases or small case series. No treatment has been generally accepted as standard therapy, although various treatments have been reported to be beneficial, including warfarin, bisphosphonates, minocycline, ceftriaxone, diltiazem, aluminium hydroxide, probenecid, intralesional corticosteroids, intravenous immunoglobulin, curettage, surgical excision, carbon dioxide laser, and extracorporeal shock wave lithotripsy.

Topics: Biopsy, Needle; Calcinosis; Ceftriaxone; Combined Modality Therapy; Drug Therapy, Combination; Education, Medical, Continuing; Evidence-Based Medicine; Female; Humans; Immunoglobulins, Intravenous; Immunohistochemistry; Laser Therapy; Lasers, Gas; Male; Minocycline; Prognosis; Recurrence; Risk Assessment; Severity of Illness Index; Skin Diseases; Treatment Outcome; Warfarin

Antibiotic-resistant organisms causing both hospital- and community-acquired complicated skin and soft-tissue infections (cSSTI) are increasingly reported. A substantial medical and economical burden associated with MRSA colonisation or infection has been documented. The number of currently available appropriate antimicrobial agents is limited. Good quality randomised, controlled clinical trial data on antibiotic efficacy and safety is available for cSSTI caused by MRSA. Linezolid, tigecycline, daptomycin and vancomycin showed efficacy and safety in MRSA-caused cSSTI. None of these drugs showed significant superiority in terms of clinical cure and eradication rates.To date, linezolid offers by far the greatest number of patients included in controlled trials with a strong tendency of superiority over vancomycin in terms of eradication and clinical success.. - Tigecycline is an alternative in polymicrobial infections except by diabetic foot infections. Daptomycin might be a treatment option for cases of cSSTI with MRSA bacteremia. cSSTI caused by resistant Gram-negative bacteria are a matter of great concern. The development of new antibiotics in this area is an urgent priority to avoid the risk of a postantibiotic era with no antimicrobial treatment options. An individual approach for every single patient is mandatory to evaluate the optimal antimicrobial treatment regimen.

Topics: Acetamides; Anti-Bacterial Agents; Daptomycin; Drug Resistance, Microbial; Humans; Linezolid; Minocycline; Oxazolidinones; Skin Diseases; Soft Tissue Infections; Tigecycline; Vancomycin

Drug-induced lupus erythematosus (DILE) is defined as an entity characterized by clinical manifestations and immunopathological serum findings similar to those of idiopathic lupus but which is temporally related to continuous drug exposure and resolves after discontinuation of the offending drug. Similar to idiopathic lupus, DILE can be divided into systemic lupus erythematosus (SLE), subacute cutaneous lupus erythematosus (SCLE) and chronic cutaneous lupus erythematosus (CCLE). Based on the literature review and retrospective analysis of our case series, we focused on the dermatological aspects of DILE. The cutaneous features of drug-induced SLE are protean, including particularly purpura, erythema nodosum and photosensitivity as well as the skin lesions characterizing both urticarial and necrotizing vasculitis. The typical laboratory profile of systemic DILE consists of positive antinuclear antibodies (ANA) and antihistone antibodies, the latter being regarded as the serum marker of this subset. The drugs most frequently implicated in the development of systemic DILE are hydralazine, procainamide, isoniazid and minocycline. Drug-induced SCLE usually presents with annular polycyclic or papulosquamous cutaneous manifestations as in the idiopathic form, but blisters or targetoid lesions mimicking erythema multiforme cannot rarely be associated. The clinical presentation is often generalized, with involvement of the lower legs that are usually spared in idiopathic SCLE. ANA and anti-Ro/SSA antibodies are usually present, whereas antihistone antibodies are uncommonly found. Drugs associated with SCLE include particularly calcium channel blockers, angiotensin-converting enzyme inhibitors, thiazide diuretics, terbinafine and the recently reported tumour necrosis factor (TNF)-alpha antagonists. Drug-induced CCLE is very rarely described in the literature and usually refers to fluorouracile agents or TNF-alpha antagonists. The picture is characterized by the occurrence of classic discoid lesions, but aspects of lupus tumidus can occasionally develop. ANA are demonstrated in around two-thirds of the cases. Management of DILE is based on the withdrawal of the offending drug. Topical and/or systemic corticosteroids and other immunosuppressive agents should be reserved for resistant cases.

Topics: Anti-Arrhythmia Agents; Anti-Bacterial Agents; Antihypertensive Agents; Antitubercular Agents; Autoantibodies; Drug-Related Side Effects and Adverse Reactions; Humans; Hydralazine; Isoniazid; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Lupus Erythematosus, Systemic; Minocycline; Procainamide; Skin Diseases

Tetracyclines are broad-spectrum antibiotics that act as such at the ribosomal level where they interfere with protein synthesis. They were first widely prescribed by dermatologists in the early 1950s when it was discovered that they were effective as a treatment for acne. More recently, biologic actions affecting inflammation, proteolysis, angiogenesis, apoptosis, metal chelation, ionophoresis, and bone metabolism have been researched. The therapeutic effects of tetracycline and its analogues in various diseases have also been investigated. These include rosacea, bullous dermatoses, neutrophilic diseases, pyoderma gangrenosum, sarcoidosis, aortic aneurysms, cancer metastasis, periodontitis, and autoimmune disorders such as rheumatoid arthritis and scleroderma. We review the nonantibiotic properties of tetracycline and its analogues and their potential for clinical application.

Topics: Acne Vulgaris; Anti-Bacterial Agents; Anti-Inflammatory Agents; Aortic Aneurysm, Abdominal; Apoptosis; Arthritis, Rheumatoid; Doxycycline; Humans; Matrix Metalloproteinases; Minocycline; Neoplasms; Neovascularization, Physiologic; Periodontitis; Rosacea; Sarcoma, Kaposi; Skin Diseases; Skin Diseases, Vesiculobullous; Tetracyclines

Topics: Anti-Bacterial Agents; Diagnosis, Differential; Humans; Hyperpigmentation; Male; Melanoma; Minocycline; Skin Diseases

Topics: Acne Vulgaris; Adult; Anti-Bacterial Agents; Female; Humans; Minocycline; Polyarteritis Nodosa; Skin Diseases

The goal of this review was to summarize the available literature covering the safety profiles of oral doxycycline and minocycline.. Scientific literature published between 1966 and August 2003 was searched using the MEDLINE, EMBASE, and Biosis databases (search terms: minocycline or doxycycline, each paired with adverse reaction, adverse event, and side effect, and doxycycline or minocycline with the limits English language, human, and clinical trials). Safety information was collected from case reports and clinical trials. Adverse event (AE) rates in the United States were calculated by comparing data from the MedWatch AE reporting program used by the US Food and Drug Administration (FDA) with the number of new prescriptions dispensed for each drug from January 1998 to August 2003.. Between 1966 and 2003, a total of 130 and 333 AEs were published in case reports of doxycycline and minocycline, respectively. In 24 doxycycline clinical trials (n = 3833) and 11 minocycline trials (n = 788), the ranges in incidence of AEs were 0% to 61% and 11.7% to 83.3%, respectively. Gastrointestinal AEs were most common with doxycycline; central nervous system and gastrointestinal AEs were most common with minocycline. From January 1998 to August 2003, the FDA MedWatch data contained 628 events for doxycycline and 1099 events for minocycline reported in the United States. Approximately 47,630,000 doxycycline and 15,234,000 minocycline new prescriptions were dispensed in the United States during that period, yielding event rates of 13 per million for doxycycline and 72 per million for minocycline, based on FDA data.. Between 1998 and 2003, doxycycline was prescribed 3 times as often as minocycline. The incidence of AEs with either drug is very low, but doxycycline had fewer reported AEs. Although more head-to-head clinical trials are needed for a direct comparison of AE frequency, these preliminary data from separate reports suggest the possibility that AEs may be less likely with doxycycline than minocycline.

Topics: Acne Vulgaris; Adverse Drug Reaction Reporting Systems; Anti-Bacterial Agents; Central Nervous System Diseases; Clinical Trials as Topic; Doxycycline; Drug Prescriptions; Gastrointestinal Diseases; Humans; Incidence; MEDLINE; Minocycline; Skin Diseases; United States; United States Food and Drug Administration

Topics: Dinitrochlorobenzene; Hexachlorocyclohexane; Humans; Liver Cirrhosis; Methotrexate; Minocycline; Photochemotherapy; PUVA Therapy; Skin Absorption; Skin Diseases; Skin Pigmentation

To evaluate the safety and efficacy of minocycline in the treatment of sarcoidosis, a nonrandomized, open study was performed in patients with cutaneous sarcoidosis.. Twelve patients with cutaneous sarcoidosis were treated with minocycline, 200 mg/d, for a median duration of 12 months. Three patients had extracutaneous lesions at the time of the study. The median follow-up was 26 months. A clinical response was observed in 10 patients, consisting of complete responses in 8 patients and partial responses in 2 patients. A progression of skin lesions was observed in 1 patient, and lesions remained stable in another patient. Adverse effects were minimal, except in 1 patient, who developed hypersensitivity syndrome. A slight hyperpigmentation occurred in 2 patients at the site of previous lesions, which completely disappeared after minocycline use was discontinued. A relapse of skin symptoms occurred after minocycline withdrawal in 3 patients, who further received doxycycline, 200 mg/d, allowing a complete remission of lesions.. These results support that minocycline and doxycycline may be beneficial for the treatment of cutaneous sarcoidosis. Randomized controlled studies are warranted for the evaluation of the true efficacy of tetracyclines in these patients.

Topics: Adolescent; Adult; Anti-Bacterial Agents; Arm; Female; Follow-Up Studies; Forehead; Humans; Male; Middle Aged; Minocycline; Radiography; Sarcoidosis; Sarcoidosis, Pulmonary; Skin Diseases; Treatment Outcome

The efficacy and safety of minocycline were compared with that of amoxicillin in the treatment of 58 patients with acute bacterial sinusitis. The most frequently isolated pathogens were streptococci, staphylococci, and Haemophilus influenzae. After therapy for a mean time of 11 days, clinical cure or improvement and bacterial eradication were evident in 100% of the patients treated with minocycline and in 95% of the patients treated with amoxicillin. Roentgenographic results indicated clearing or improvement in 91% of the minocycline recipients and in 70% of those who received amoxicillin. These differences between treatments were not statistically significant. A low incidence of generally mild adverse clinical experiences occurred in both treatment groups. Thus, minocycline and amoxicillin were equally safe and effective in the treatment of these patients with acute bacterial sinusitis.

Topics: Adolescent; Adult; Aged; Amoxicillin; Bacterial Infections; Child; Female; Gastrointestinal Diseases; Haemophilus influenzae; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Minocycline; Radiography; Random Allocation; Sinusitis; Skin Diseases; Staphylococcus aureus; Streptococcus; Tetracyclines

Anti-epidermal growth factor receptor (EGFR) antibodies often cause skin toxicities. Preemptive skin treatments using systemic antibiotics with or without topical steroid are reportedly effective although the most suitable method remains unclear. This study aimed to determine whether combination prophylaxis using systemic minocycline and topical steroid is superior to minocycline alone in a real-world metastatic colorectal cancer (mCRC) treatment.. Patients with mCRC (n = 87) who received anti-EGFR monoclonal antibodies were retrospectively assessed. The primary objective was to compare the incidence of grade ≥ 2 overall skin toxicities during all treatment periods between the control group receiving prophylactic minocycline 100 mg/day, and the combination prophylaxis group receiving minocycline 100 mg/day + topical steroid. The incidence of each skin symptom was also evaluated.. The incidence of grade ≥ 2 overall skin toxicities was 63.6% in the control and 56.9% in the combination groups, with no significant difference (P = 0.63). Similarly, the incidence of grade ≥ 2 dry skin, fissures, paronychia, and pruritus did not significantly differ. In addition, incidence of all-grade skin toxicities was not different. However, the incidence of grade ≥ 2 papulopustular rashes was significantly lower in the combination group (23.1% vs. 50.0%, P = 0.03). Propensity score-matched analysis supported these results. Multivariate logistic regression analysis showed no significant association between combination prophylaxis and grade ≥ 2 overall skin toxicities, but it did show a reduction in grade ≥ 2 papulopustular rashes.. Adding topical steroids to systemic minocycline did not mitigate grade ≥ 2 overall skin toxicities induced by anti-EGFR antibodies; however, it significantly improved papulopustular rashes.

Topics: Colonic Neoplasms; Exanthema; Humans; Intercellular Signaling Peptides and Proteins; Minocycline; Ointments; Retrospective Studies; Skin Diseases; Steroids

Topics: Aged; Anti-Bacterial Agents; Humans; Male; Minocycline; Pigmentation Disorders; Sclera; Scleral Diseases; Skin; Skin Diseases; Tooth Discoloration

Cancer drug treatment is often discontinued because of skin disorder aggravation. However, information on risk factors for skin disorders caused by anti-epidermal growth factor receptor (EGFR) antibody drugs is limited. The aim of this study was to analyse the factors associated with skin disorders caused by anti-EGFR antibody drugs and establish a method to minimize such aggravations.. We retrospectively examined 67 colorectal cancer patients treated with anti-EGFR antibody drugs for the first time.. A higher proportion of males than females experienced drug withdrawal, dose reduction or treatment discontinuation. The multiple logistic regression analysis revealed body weight as a risk factor affecting drug withdrawal, dose reduction or treatment discontinuation because of an acneiform rash. An examination of methods to avoid the aggravation of skin disorders revealed the acneiform rash grade in patients who received prophylactic minocycline was significantly lower than that in patients who did not receive prophylactic minocycline. Furthermore, among patients with grade 1 acneiform rash at the initiation of minocycline, the proportion of those who withdrew, required dose reduction or discontinued treatment was lower than that among patients with grade 2 acneiform rash.. High body weight was identified as a novel factor for skin disorder aggravation caused by anti-EGFR antibody drugs. The aggravation of skin disorders during cancer treatment with anti-EGFR antibody drugs can potentially be avoided by carefully observing the onset of acneiform rash in affected patients with high body weight and using minocycline prophylactically or as an early-stage intervention.

Topics: Age Factors; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Logistic Models; Male; Middle Aged; Minocycline; Patient Dropouts; Quality of Life; Retrospective Studies; Sex Factors; Skin Diseases

While epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) exert a breakthrough effect, the incidence of skin disorders as a side effect has significantly reduced patients' quality of life. This study aimed to develop a treatment for inflammatory ulcers as one of the side effects of afatinib (Giotrif®), a second-generation EGFR-TKI, and established a skin disorder mouse model to investigate the protective effect of minocycline.. First, under inhalation anesthesia with isoflurane, the back of a male ddy mouse was shaved, and afatinib petrolatum was applied alone or in combination with minocycline to observe the state of the skin and measure transepidermal water transpiration (TEWL). Next, afatinib was administered orally to mice, and minocycline petrolatum was applied to observe whether the skin disorder was prevented and its effect on repair of the skin disorder.. Skin injury occurred on the back of the mouse following afatinib (1 mg/g in petrolatum) application, and scab formation was observed. Application of minocycline prevented and improved the skin disorder caused by afatinib. When the minocycline-petrolatum mixture was applied to the mouse that developed the skin disorder, a significant improvement in TEWL was observed, and skin repair was observed macroscopically.. These results suggest that minocycline petrolatum applied locally prevents and repairs afatinib-induced skin disorders of non-small cell lung cancer patients. Histological examination of skin has provided insights into the mechanism of the occurrence of afatinib-related skin disorder and suggested the efficacy of minocycline topical application in clinical practice.

Topics: Afatinib; Animals; Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Humans; Lung Neoplasms; Male; Mice; Minocycline; Protein Kinase Inhibitors; Quality of Life; Skin Diseases

In paediatric rosacea, ocular symptoms are often predominant. Literature about systemic therapy of paediatric ocular rosacea is sparse, though.. Analysis of children with ocular rosacea treated systemically, particularly addressing remission and recurrence rates.. Retrospective study reviewing the medical records of children with ocular rosacea treated with systemic antibiotic therapy. Nine of 19 patients were chosen for detailed analysis. To our knowledge, this is the first study in paediatric ocular rosacea requiring systemic therapy with a larger patient group and a longer follow-up (mean follow-up = 30.2 months).. 17 patients (89.5%) suffered from blepharitis, 15 patients (78.9%) from conjunctivitis, twelve patients (63.2%) from chalazia/styes and nine female patients (47.4%) from corneal involvement. We used erythromycin (n = 9) or roxithromycin (n = 1) in patients younger than 8 years and doxycycline (n = 8) or minocycline (n = 1) in patients older than 8 years. Seven of nine patients treated with erythromycin, one of eight patients treated with doxycycline and the patient treated with minocycline achieved a complete remission of ocular and cutaneous symptoms. Two of nine patients treated with erythromycin, seven of eight patients treated with doxycycline and the patient treated with roxithromycin achieved a partial remission. Relapses occurred in the patient treated with minocycline (cutaneous), two of eight patients treated with doxycycline (ocular and cutaneous) and one of nine patients treated with erythromycin (cutaneous).. To achieve a complete remission of cutaneous and ocular rosacea, a long-term anti-inflammatory treatment of at least 6 months is necessary. The relapse rates seem to be lower than in adults especially in the patients treated with erythromycin.

Topics: Adolescent; Child; Child, Preschool; Doxycycline; Erythromycin; Eye Diseases; Female; Humans; Infant; Male; Minocycline; Recurrence; Remission Induction; Retrospective Studies; Rosacea; Roxithromycin; Skin Diseases

Silicone oil injections are often used for soft tissue augmentation and local and general adverse effects occurring from a few months to 15 years after injection have been reported. Here, we present a case of delayed granuloma formation due to liquid injectable silicone with large extent of involvement, which precluded surgical removal. Our patient was successfully treated with minocycline, considering its anti-inflammatory, immunomodulating and antigranulomatous properties. This case presents minocycline monotherapy as a useful treatment option for the management of severe granuloma induced by silicone use when surgical excision is not possible.

Topics: Adult; Anti-Bacterial Agents; Female; Granuloma, Foreign-Body; Humans; Minocycline; Silicone Oils; Skin Diseases

Topics: Adalimumab; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Drug Therapy, Combination; Histiocytosis, Non-Langerhans-Cell; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Minocycline; Remission Induction; Skin Diseases

Topics: Anti-Bacterial Agents; Female; Humans; Male; Minocycline; Sarcoidosis; Skin Diseases

Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Female; Humans; Male; Minocycline; Retrospective Studies; Sarcoidosis; Sex Factors; Skin Diseases; Treatment Outcome

Hypopigmented patches and plaques are a rare presentation of cutaneous sarcoidosis. We describe a case of generalized hypopigmented cutaneous sarcoidosis that showed good response to minocycline therapy.

Topics: Anti-Bacterial Agents; Humans; Hypopigmentation; Male; Middle Aged; Minocycline; Sarcoidosis; Skin Diseases; Treatment Outcome

Topics: Acne Vulgaris; Humans; Male; Middle Aged; Minocycline; Parkinson Disease; Skin Diseases; Treatment Outcome

A 24-year-old man had an asymptomatic rash on his chest and arms for one year. On his chest, there were brown confluent plaques in a reticulate pattern. A scraping for fungus was negative. A biopsy showed papillomatosis, orthokeratosis, and melanin pigment at the basal layer of the epidermis. The patient was started on a six-week course of minocycline twice/day. Six weeks later, the patient was completely clear of the rash. Confluent and reticulate papillomatosis is an uncommon dermatosis that tends to occur on the chest. The pathogenesis is unknown. Minocycline has been reported to work well in the treatment of this dermatosis.

Topics: Adult; Anti-Bacterial Agents; Humans; Male; Minocycline; Pigmentation Disorders; Skin; Skin Diseases

Topics: Administration, Oral; Adult; Choroid Diseases; Conjunctival Diseases; Female; Humans; Kidney Diseases; Lacrimal Apparatus Diseases; Minocycline; Obesity, Morbid; Peptidyl-Dipeptidase A; Sarcoidosis; Sarcoidosis, Pulmonary; Skin Diseases; Tomography, X-Ray Computed

Topics: Acne Vulgaris; Adult; Anti-Bacterial Agents; Female; Humans; Minocycline; Polyarteritis Nodosa; Skin Diseases

A new broad spectrum antibiotic with activity against many drug-resistant organisms.

Topics: Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Infusion Pumps; Minocycline; Nausea; Skin Diseases; Tigecycline; Vomiting

Topics: Anti-Bacterial Agents; Female; Granuloma, Foreign-Body; Humans; Middle Aged; Minocycline; Prostheses and Implants; Silicone Gels; Skin Diseases

Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Cephalosporins; Cohort Studies; Contraceptives, Oral; Drug Interactions; Female; Humans; Minocycline; Pregnancy; Retrospective Studies; Skin Diseases

Milia en plaque is an unusual eruption typically occurring in the retroauricular area. Two cases of this disorder occurring in a novel position and treated with oral minocycline are now reported.

Topics: Anti-Bacterial Agents; Ear Diseases; Ear, External; Humans; Male; Middle Aged; Minocycline; Skin Diseases

Sweet's syndrome (acute febrile neutrophilic dermatosis) occurred in a 29-year-old woman with acne. Although Sweet's syndrome initially seemed to be triggered by an acute acne flare, minocycline could later be identified as the causal agent. Because this could be confirmed in an oral provocation test, this seems to be the first case of a true connection between Sweet's syndrome and its induction by a drug, namely minocycline.

Topics: Acne Vulgaris; Acute Disease; Adult; Drug Eruptions; Female; Humans; Minocycline; Neutrophils; Recurrence; Skin Diseases; Syndrome

Topics: Appendectomy; Female; Humans; Middle Aged; Minocycline; Skin Diseases; Syndrome; Yersinia enterocolitica; Yersinia Infections

Topics: Humans; Minocycline; Mycobacterium; Mycobacterium Infections; Nontuberculous Mycobacteria; Rifampin; Skin Diseases; Tuberculin Test